Selected research
Industry Research
Kidney Cancer or Renal Cancer Industry Research Report 2026
Market perspective
The global Kidney Cancer or Renal Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Kidney Cancer or Renal Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Kidney Cancer or Renal Cancer market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Kidney Cancer or Renal Cancer market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Kidney Cancer or Renal Cancer include Takeda, Novartis, Merck & Co, Roche, Pfizer, Seagen, Merck KGaA, GSK and Gilead Sciences, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Kidney Cancer or Renal Cancer market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Kidney Cancer or Renal Cancer.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Kidney Cancer or Renal Cancer Market by Company
Takeda
Novartis
Merck & Co
Roche
Pfizer
Seagen
Merck KGaA
GSK
Gilead Sciences
Eli Lilly
Bristol-Myers Squibb
AstraZeneca
Amgen
Kidney Cancer or Renal Cancer Segment by Type
Targeted Therapy
Chemotherapy
Immunotherapy
Kidney Cancer or Renal Cancer Segment by Application
Hospital
Pharmacy
Other
Kidney Cancer or Renal Cancer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer or Renal Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer or Renal Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer or Renal Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Kidney Cancer or Renal Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Targeted Therapy
- Chemotherapy
- Immunotherapy
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- Takeda
- Novartis
- Merck & Co
- Roche
- Pfizer
- Seagen
- Merck KGaA
- GSK
- Gilead Sciences
- Eli Lilly
- Bristol-Myers Squibb
- AstraZeneca
- Amgen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Kidney Cancer or Renal Cancer by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Targeted Therapy
- 2.2.3 Chemotherapy
- 2.2.4 Immunotherapy
- 2.3 Kidney Cancer or Renal Cancer by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Kidney Cancer or Renal Cancer Breakdown Data by Type
- 3.1 Global Kidney Cancer or Renal Cancer Historic Market Size by Type (2021-2026)
- 3.2 Global Kidney Cancer or Renal Cancer Forecasted Market Size by Type (2027-2032)
4 Kidney Cancer or Renal Cancer Breakdown Data by Application
- 4.1 Global Kidney Cancer or Renal Cancer Historic Market Size by Application (2021-2026)
- 4.2 Global Kidney Cancer or Renal Cancer Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Kidney Cancer or Renal Cancer Market Perspective (2021-2032)
- 5.2 Global Kidney Cancer or Renal Cancer Growth Trends by Region
- 5.2.1 Global Kidney Cancer or Renal Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Kidney Cancer or Renal Cancer Historic Market Size by Region (2021-2026)
- 5.2.3 Kidney Cancer or Renal Cancer Forecasted Market Size by Region (2027-2032)
- 5.3 Kidney Cancer or Renal Cancer Market Dynamics
- 5.3.1 Kidney Cancer or Renal Cancer Industry Trends
- 5.3.2 Kidney Cancer or Renal Cancer Market Drivers
- 5.3.3 Kidney Cancer or Renal Cancer Market Challenges
- 5.3.4 Kidney Cancer or Renal Cancer Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Kidney Cancer or Renal Cancer Players by Revenue
- 6.1.1 Global Top Kidney Cancer or Renal Cancer Players by Revenue (2021-2026)
- 6.1.2 Global Kidney Cancer or Renal Cancer Revenue Market Share by Players (2021-2026)
- 6.2 Global Kidney Cancer or Renal Cancer Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Kidney Cancer or Renal Cancer Head Office and Area Served
- 6.4 Global Kidney Cancer or Renal Cancer Players, Product Type & Application
- 6.5 Global Kidney Cancer or Renal Cancer Manufacturers Established Date
- 6.6 Global Kidney Cancer or Renal Cancer Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Kidney Cancer or Renal Cancer Market Size (2021-2032)
- 7.2 North America Kidney Cancer or Renal Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Kidney Cancer or Renal Cancer Market Size by Country (2021-2026)
- 7.4 North America Kidney Cancer or Renal Cancer Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Kidney Cancer or Renal Cancer Market Size (2021-2032)
- 8.2 Europe Kidney Cancer or Renal Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Kidney Cancer or Renal Cancer Market Size by Country (2021-2026)
- 8.4 Europe Kidney Cancer or Renal Cancer Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Kidney Cancer or Renal Cancer Market Size (2021-2032)
- 9.2 Asia-Pacific Kidney Cancer or Renal Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Kidney Cancer or Renal Cancer Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Kidney Cancer or Renal Cancer Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Kidney Cancer or Renal Cancer Market Size (2021-2032)
- 10.2 South America Kidney Cancer or Renal Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Kidney Cancer or Renal Cancer Market Size by Country (2021-2026)
- 10.4 South America Kidney Cancer or Renal Cancer Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Kidney Cancer or Renal Cancer Market Size (2021-2032)
- 11.2 Middle East & Africa Kidney Cancer or Renal Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Kidney Cancer or Renal Cancer Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Kidney Cancer or Renal Cancer Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.1.4 Takeda Kidney Cancer or Renal Cancer Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.2.4 Novartis Kidney Cancer or Renal Cancer Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Merck & Co
- 12.3.1 Merck & Co Company Information
- 12.3.2 Merck & Co Business Overview
- 12.3.3 Merck & Co Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.3.4 Merck & Co Kidney Cancer or Renal Cancer Product Portfolio
- 12.3.5 Merck & Co Recent Developments
- 12.4 Roche
- 12.4.1 Roche Company Information
- 12.4.2 Roche Business Overview
- 12.4.3 Roche Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.4.4 Roche Kidney Cancer or Renal Cancer Product Portfolio
- 12.4.5 Roche Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.5.4 Pfizer Kidney Cancer or Renal Cancer Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Seagen
- 12.6.1 Seagen Company Information
- 12.6.2 Seagen Business Overview
- 12.6.3 Seagen Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.6.4 Seagen Kidney Cancer or Renal Cancer Product Portfolio
- 12.6.5 Seagen Recent Developments
- 12.7 Merck KGaA
- 12.7.1 Merck KGaA Company Information
- 12.7.2 Merck KGaA Business Overview
- 12.7.3 Merck KGaA Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.7.4 Merck KGaA Kidney Cancer or Renal Cancer Product Portfolio
- 12.7.5 Merck KGaA Recent Developments
- 12.8 GSK
- 12.8.1 GSK Company Information
- 12.8.2 GSK Business Overview
- 12.8.3 GSK Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.8.4 GSK Kidney Cancer or Renal Cancer Product Portfolio
- 12.8.5 GSK Recent Developments
- 12.9 Gilead Sciences
- 12.9.1 Gilead Sciences Company Information
- 12.9.2 Gilead Sciences Business Overview
- 12.9.3 Gilead Sciences Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.9.4 Gilead Sciences Kidney Cancer or Renal Cancer Product Portfolio
- 12.9.5 Gilead Sciences Recent Developments
- 12.10 Eli Lilly
- 12.10.1 Eli Lilly Company Information
- 12.10.2 Eli Lilly Business Overview
- 12.10.3 Eli Lilly Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.10.4 Eli Lilly Kidney Cancer or Renal Cancer Product Portfolio
- 12.10.5 Eli Lilly Recent Developments
- 12.11 Bristol-Myers Squibb
- 12.11.1 Bristol-Myers Squibb Company Information
- 12.11.2 Bristol-Myers Squibb Business Overview
- 12.11.3 Bristol-Myers Squibb Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.11.4 Bristol-Myers Squibb Kidney Cancer or Renal Cancer Product Portfolio
- 12.11.5 Bristol-Myers Squibb Recent Developments
- 12.12 AstraZeneca
- 12.12.1 AstraZeneca Company Information
- 12.12.2 AstraZeneca Business Overview
- 12.12.3 AstraZeneca Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.12.4 AstraZeneca Kidney Cancer or Renal Cancer Product Portfolio
- 12.12.5 AstraZeneca Recent Developments
- 12.13 Amgen
- 12.13.1 Amgen Company Information
- 12.13.2 Amgen Business Overview
- 12.13.3 Amgen Revenue in Kidney Cancer or Renal Cancer Business (2021-2026)
- 12.13.4 Amgen Kidney Cancer or Renal Cancer Product Portfolio
- 12.13.5 Amgen Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst